Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus

Author:

Liou Jyh-MingORCID,Malfertheiner Peter,Lee Yi-ChiaORCID,Sheu Bor-ShyangORCID,Sugano Kentaro,Cheng Hsiu-Chi,Yeoh Khay-GuanORCID,Hsu Ping-I,Goh Khean-Lee,Mahachai Varocha,Gotoda TakujiORCID,Chang Wei-Lun,Chen Mei-Jyh,Chiang Tsung-Hsien,Chen Chieh-Chang,Wu Chun-YingORCID,Leow Alex Hwong-Ruey,Wu Jeng-Yih,Wu Deng-Chyang,Hong Tzu-Chan,Lu HongORCID,Yamaoka YoshioORCID,Megraud Francis,Chan Francis K LORCID,Sung Joseph JY,Lin Jaw-TownORCID,Graham David YORCID,Wu Ming-ShiangORCID,El-Omar Emad MORCID

Abstract

ObjectiveA global consensus meeting was held to review current evidence and knowledge gaps and propose collaborative studies on population-wide screening and eradication of Helicobacter pylori for prevention of gastric cancer (GC).Methods28 experts from 11 countries reviewed the evidence and modified the statements using the Delphi method, with consensus level predefined as ≥80% of agreement on each statement. The Grading of Recommendation Assessment, Development and Evaluation (GRADE) approach was followed.ResultsConsensus was reached in 26 statements. At an individual level, eradication of H. pylori reduces the risk of GC in asymptomatic subjects and is recommended unless there are competing considerations. In cohorts of vulnerable subjects (eg, first-degree relatives of patients with GC), a screen-and-treat strategy is also beneficial. H. pylori eradication in patients with early GC after curative endoscopic resection reduces the risk of metachronous cancer and calls for a re-examination on the hypothesis of ‘the point of no return’. At the general population level, the strategy of screen-and-treat for H. pylori infection is most cost-effective in young adults in regions with a high incidence of GC and is recommended preferably before the development of atrophic gastritis and intestinal metaplasia. However, such a strategy may still be effective in people aged over 50, and may be integrated or included into national healthcare priorities, such as colorectal cancer screening programmes, to optimise the resources. Reliable locally effective regimens based on the principles of antibiotic stewardship are recommended. Subjects at higher risk of GC, such as those with advanced gastric atrophy or intestinal metaplasia, should receive surveillance endoscopy after eradication of H. pylori.ConclusionEvidence supports the proposal that eradication therapy should be offered to all individuals infected with H. pylori. Vulnerable subjects should be tested, and treated if the test is positive. Mass screening and eradication of H. pylori should be considered in populations at higher risk of GC.

Funder

Takeda Taiwan Co. Ltd

Ministry of Education (MOE) in Taiwan

Ministry of Health and Welfare of Taiwan

the Swiss Pharmaceutical Co., Ltd

Australian Federal Government to the St George and Sutherland Medical Research Foundation.

the Liver Disease Prevention & Treatment Research Foundation, Taiwan

the Eisai Co. Ltd

Texas Medical Center Digestive Diseases Center

the Harvester Trading Co. LTD.

the Panion & BF Biotech Inc.

National Taiwan University Hospital

Gastroenterological Society of Taiwan

Office of Research and Development Medical Research Service Department of Veterans Affairs, Public Health Service

Ministry of Science and Technology of Taiwan

Publisher

BMJ

Subject

Gastroenterology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3